At a glance
ClinicalIndex Comparison RecordPhase 2Active· 173 enrolled
Drug / intervention
AB-106drug
Likely dose
AB-106 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open Label, Single Arm Phase 2 Study of AB-106 in the Treatment of Locally Advanced and Metastatic NSCLC
In Brief
A Phase 2 clinical trial evaluating AB-106 for Non Small Cell Lung Cancer. Active but no longer recruiting, targeting 173 participants across 1 site.
Detailed Summary
The purpose of the study is to evaluate safety, pharmacokinetics and efficacy of AB-106 monotherapy in the treatment of advanced NSCLC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 2Active
2021202220232024202520262027
First PostedMay 2020
Enrollment StartJul 2020
Primary CompletionJun 2024
TodayJul 2026
Study CompletionJun 2027
First PostedMay 20, 2020
Enrollment StartJul 7, 2020
Primary CompletionJun 7, 2024
Study CompletionJun 1, 2027
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 6.1 years ago
Interventions
AB-106drug
Stage 1: 400mg QD for 3 patients and 600mg QD for 3 patients Stage 2: 600mg QD